We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current TXG market cap is 3.31B. The company's latest EPS is USD -2.1407 and P/E is -12.85.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 131.07M | 156.23M | 134.29M | 146.82M | 153.64M |
| Operating Income | -40M | -27.3M | -51.99M | -63.36M | -94.8M |
| Net Income | -41.91M | -17.22M | -50.75M | -62.41M | -92.99M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 245.89M | 298.85M | 491.15M | 516.41M | 618.73M |
| Operating Income | -30.57M | -534.14M | -52.25M | -167.94M | -260.43M |
| Net Income | -31.25M | -542.73M | -58.22M | -166M | -255.1M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 996.21M | 1.03B | 1.01B | 989.64M | 948.54M |
| Total Liabilities | 220.42M | 223.24M | 211.65M | 196.34M | 203.32M |
| Total Equity | 775.79M | 805.74M | 802.39M | 793.3M | 745.22M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 605.92M | 929.34M | 1.02B | 1.03B | 965.14M |
| Total Liabilities | 185.84M | 190.27M | 201.26M | 223.24M | 224.1M |
| Total Equity | 420.08M | 739.07M | 817.57M | 805.74M | 741.04M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -47.33M | -33.61M | -4.13M | -15.65M | -40.96M |
| Investing | -317.72M | -350.89M | 119.96M | 115.49M | 120.39M |
| Financing | 10.82M | 15.82M | -3.41M | 3.68M | 8.06M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 34.63M | -217.9M | -21.37M | -33.61M | -15.2M |
| Investing | -42.77M | -38.39M | -106.73M | -350.89M | 133.49M |
| Financing | 414.59M | 468.91M | 35.3M | 15.82M | 13.67M |
| Market Cap | 3.31B |
| Price to Earnings Ratio | -12.85 |
| Price to Sales Ratio | 5.3 |
| Price to Cash Ratio | 9.12 |
| Price to Book Ratio | 4.42 |
| Dividend Yield | - |
| Shares Outstanding | 119.17M |
| Average Volume (1 week) | 2.99M |
| Average Volume (1 Month) | 2.01M |
| 52 Week Change | -48.48% |
| 52 Week High | 63.57 |
| 52 Week Low | 24.60 |
| Spread (Intraday) | 0.01 (0.04%) |
| Company Name | 10x Genomics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.10xgenomics.com |
| Industry | lab analytical instruments (3826) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
